Webinar on Zoom, recordings will become available to all delegates approximately 3 weeks after the event.

• Update in Lung Cancer – Dr Nadia Yousef Consultant Medical Oncologist Royal Marsden Hospital
Dr Yousaf is a consultant medical oncologist with both an NHS and private practice at The Royal Marsden Hospital. She is a specialist in the treatment of lung cancer, mesothelioma and thymoma using systemic anticancer therapies which includes immunotherapy, chemotherapy and targeted therapies.
Dr Yousaf qualified from the University of Newcastle upon Tyne in 2002. She completed her medical oncology training at The Royal Marsden Hospital and was appointed as a consultant at the Royal Marsden in 2016. She also completed a period of research leading to the award of an MD(res) at the University of Leicester where her area of interest was using digital technologies to monitor patients.
Dr Yousaf was appointed Honorary Faculty at the Institute of Cancer research in 2020. She has authored multiple peer-reviewed publications and undertakes a variety of clinical research. She has also served as a clinical expert for NICE.
Dr Yousaf has also been awarded an MBA after a period of study at London Business School. She set up the Royal Marsden Hospital Acute Oncology Service and the Royal Marsden Hospital and Royal Brompton Hospital Thoracic Cancer service. She remains clinical lead for the Thoracic Cancer service.
In addition, she continues to pursue her interest in Digital Health as The Chief Clinical Information Officer.

• Update in Myeloma – Dr Karthik Ramasamay Consultant Haematologist OUH
Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre https://oxford-myeloma.org.uk, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group. He is the Divisional Lead for Cancer Research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK. Since 2021 Karthik chairs the NIHR Haem Onc and Lymphoma oversight group. He is an Executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance. Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy is a Chief Investigator of national myeloma studies and his translational research interests are early diagnosis of myeloma with current Medical research council fellowship and cancer research UK charitable funding, bone disease and myeloma drug resistance mechanisms. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Karthik has published over 100 papers and authored textbooks/ chapters on myeloma.

• Cancer in Pregnancy – Professor Catherine Atken Consultant in Maternal and Fetal Medicine Cambridge University Hospitals.
Professor Catherine Aiken
Professor Catherine Aiken is a clinician scientist at the University of Cambridge. She leads a research group that focuses on understanding the long-term outcomes of complex pregnancies. She has published >100 peer-reviewed papers and currently is the Chief Investigator of several ongoing studies. Her clinical work is focused on caring for women with complex pregnancies within the East of England Maternal Medicine Network. Professor Aiken is also the Associate Training Programme director for academic trainees in Obstetrics and Gynaecology in the East of England and a Fellow and Director of Studies for clinical medical students at Trinity College, Cambridge.

• Update in Head and Neck – Dr Ketan Shah Consultant OUH
Dr Ketan Shah is a Consultant Clinical Oncologist treating Breast and Head & Neck Cancers. He qualified in Cambridge and Oxford and completed oncology training at the Royal Marsden Hospital and Oxford Deanery, including a DPhil in Radiobiology studying biomarkers and imaging of radiotherapy effectiveness.
After a Head & Neck fellowship in Melbourne, he became a Consultant Clinical Oncologist in Oxford. He was Head of OUH Radiotherapy from 2021 to 2025. He chairs the Oxford H&N MDT and is Clinical Lead for Oncology for the NHSE GIRFT programme for H&N Cancer.

• Update in sarcoma - Professor Robin Jones, Royal Marsden
Professor Jones is a medical oncologist specialising in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2015 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Centre in Seattle.

The programme for 2025 is currently in development. For an example, please see the 2024 programme linked in the description.

Following the study day participants will:
- Have gained a deeper understanding of the current management of the tumour sites considered
- Be able to use the knowledge gained to help with the management of patients
- Be able to use new knowledge to aid in prognostication
- Have had an opportunity to ask questions and engage with the speakers to enable the translation of knowledge into practice